We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

X4 Pharmaceuticals Inc (XFOR) NPV

Sell:$0.35 Buy:$0.37 Change: $0.028 (8.23%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$0.35
Buy:$0.37
Change: $0.028 (8.23%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:$0.35
Buy:$0.37
Change: $0.028 (8.23%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Contact details

Address:
61 NORTH BEACON STREET, 4TH FLOOR
BOSTON
02134
United States
Telephone:
+1 (857) 5298300
Website:
https://www.x4pharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XFOR
ISIN:
US98420X1037
Market cap:
$58.05 million
Shares in issue:
170.55 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Paula Ragan
    President, Chief Executive Officer, Secretary, Director
  • Adam Mostafa
    Chief Financial Officer, Treasurer, Corporate Secretary
  • Mary Dibiase
    Chief Operating Officer
  • Arthur Taveras
    Chief Scientific Officer
  • Christophe Arbet-engels
    Chief Medical Officer
  • Mark Baldry
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.